Valuation
- Market cap
- 480,842,000
- Revenue TTM
- $175,110,000
- Net income TTM
- $-221,250,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -126.35%
- Debt to equity
- -0.48
Trading
- Volume
- 2,162,800
- Avg volume
- 1,464,076
- Day's range
- $5.50 – $6.11
- Shares out
- 81,292,000
- Stochastic %K
- 33%
- Beta
- 0.69
- Analysts
- Moderate Buy
- Price target
- $19.64
Company profile
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical t...
Show more
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 877 742 8466
- Website
- https://www.phathompharma.com
- Address
- 100 Campus Drive, Suite 102, Florham Park, United States
Latest news
No headlines yet.
Stocktwits
RandyLaheyCoreyTrevor
Nov 3, 8:46 PM
0 replies
Walleyeslayer
Nov 3, 8:10 PM
$PHAT lower and lower. Can’t imagine we don’t see another short push to mid 4’s. I keep adding monthly. 🤦♂️🤷🏻♂️💪
0 replies
Fire7878
Nov 3, 6:59 PM
$PHAT i hope the analyst are right, but organic growth trajectory based on actuals through 2026 guidance indicate a sub 480m peak. They have debt and royality obligations that need to be repaid, along with balence sheet and revenue covents. My point is some material cataylst / strategic changes need to happen to impact that trajectory. 600m might be too optimistic.
1 replies
RandyLaheyCoreyTrevor
Nov 3, 6:43 PM
$PHAT should be 0.00 any day now
0 replies
yekoiob
Nov 3, 5:07 PM
$PHAT consensus from 11 sell-side analysts covering PHAT. The guy who said 600M came out of nowhere
0 replies
Valueforall
Nov 3, 5:00 PM
$PHAT this is a weak bear case
ignoring the fact that Phathom's gross margins are ~80% and operating cash flow is already turning positive at ~
$340M/year run-rate and speaking bk makes your argument bunk
0 replies
